Regeneron Warns of Slow Praluent Uptake, While Eylea Fuels Growth
This article was originally published in Scrip
Executive Summary
Regeneron Pharmaceuticals and big pharma partner Sanofi are distributing free samples of the new cholesterol therapy Praluent (alirocumab) to patients who are awaiting insurance coverage decisions, Regeneron senior vice president of commercial Robert Terifay said during the company's Aug. 4 earnings call, while also warning that this will make it hard to assess uptake of the PCSK9 inhibitor.